Tetraphase Pharmaceu (TTPH) 3.78 $TTPH Tetraphase

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:13 AM

Tetraphase Pharmaceu (TTPH) 3.78 $TTPH

Tetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 9:10 a.m. Eastern Time at Le Parker Meridien Hotel in New York City.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Thu Aug 04, 3:52PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended June 30, 2016, and provided an overview of certain corporate achievements and plans.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria
GlobeNewswire - Mon Aug 01, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and life-threatening bacterial infections, including those caused by pathogens otherwise resistant to current treatment options.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:30 p.m. Eastern Time at The St. Regis New York Hotel in New York City.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016
GlobeNewswire - Mon May 23, 7:30AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its TP-271 program.
TTPH: 3.78 (-0.02)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 80.93 (+0.37), TTPH: 3.78 (-0.02), TRVN: 6.77 (-0.01), ADRO: 14.22 (+0.13), ANAC: 99.06 (-0.14)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 80.93 (+0.37), TRVN: 6.77 (-0.01), TTPH: 3.78 (-0.02), VRTX: 94.75 (+0.24), ADRO: 14.22 (+0.13), AMGN: 170.13 (+0.07), ANAC: 99.06 (-0.14)

Nordstrom and Wal-Mart fall, Shake Shack and Nvidia jump
AP - Fri May 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
TTPH: 3.78 (-0.02), SHAK: 35.57 (+0.27), WMT: 72.84 (+1.40), JWN: 51.03 (+0.57), CXR.TO: 11.04 (-0.38), NTK: 85.94 (-0.05), CXRX: 8.43 (-0.28), NVDA: 63.15 (+1.81)

Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status
GlobeNewswire - Thu May 12, 3:05PM CDT
- Additional phase 3 clinical trial in cIAI planned to support NDA filing -
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:30PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2016.
TTPH: 3.78 (-0.02)

Buying Stocks: Investors Are Considering These on Thursday April 7
ACCESSWIRE - Thu Apr 07, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / April 7, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. CANN, COOL, TTPH, and EKSO have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
TTPH: 3.78 (-0.02), COOL: 3.75 (-0.09), EKSO: 3.89 (+0.04)

Tetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its preclinical TP-6076 program.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals to Present at Needham Conference 2016
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15 Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
TTPH: 3.78 (-0.02)

EQUITY UPDATE: Goldberg Law PC Files Securities Class Action Lawsuit against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Mar 25, 2:14PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline. The new lawsuit has been filed on behalf of options purchasers and sellers.
TTPH: 3.78 (-0.02)

IMPORTANT DEADLINE REMINDER: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 25, 9:50AM CDT
Khang & Khang LLP (the "Firm"

announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive (the "Class Period"

, are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.78 (-0.02)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. and Lead Plaintiff Deadline: March 28, 2016
ACCESSWIRE - Fri Mar 25, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 25, 2016 / Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of Massachusetts on behalf of those who purchased shares of Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH), during the period between March 5, 2015 and September 9, 2015 inclusive (the "Class Period"

.
TTPH: 3.78 (-0.02)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
PR Newswire - Thu Mar 24, 1:47PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
TTPH: 3.78 (-0.02)

EQUITY ALERT UPDATE: Rosen Law Firm Expands Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. on Behalf of Options Purchasers and Sellers
BusinessWire - Wed Mar 23, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of all purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Tetraphase Pharmaceuticals investors under the federal securities laws.
TTPH: 3.78 (-0.02)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm
BusinessWire - Wed Feb 10, 3:05PM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.78 (-0.02)

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Tetraphase Pharmaceuticals, Inc. -- TTPH
GlobeNewswire - Wed Feb 10, 10:03AM CST
Rigrodsky & Long, P.A.:
TTPH: 3.78 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...